NCT04799002RecruitingPhase 3
Topotecan and Melphalan for Retinoblastoma
Choice of Topotecan or Melphalan in Retinoblastoma Patients
Source: ClinicalTrials.gov · Last updated 16 Mar 2021 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 12 Mar 2021
- Start date
- 11 Mar 2021
- Primary completion date
- 30 Dec 2024
- Lead sponsor
- Sun Yat-sen University
- Diseases
- Childhood cancers
- NCT number
- NCT04799002
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 50
- From 11 Mar 2021 to the primary completion date, 30 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- disease progression during follow-up
Who the study is looking for
- diagnosed as retinoblastoma
- receiving eyeball-sparing treatment
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sun Yat-sen University Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.